Integration of miRNA profiles and clinical data for early risk assessment of bronchopulmonary dysplasia in VLBW and ELBW newborn infants: a discovery study - Takeaways - MDSpire

Integration of miRNA profiles and clinical data for early risk assessment of bronchopulmonary dysplasia in VLBW and ELBW newborn infants: a discovery study

  • By

  • Iskander Isgandarov

  • Arailym Abilbayeva

  • Anel Tarabayeva

  • Dinara Yelyubayeva

  • Nishankul Bozhbanbayeva

  • Ingkar Okhas

  • Nuray Shaktay

  • Dana Yerbolat

  • Kristina Kovaleva

  • Zhanar Akhmetova

  • Zulfiya Kachiyeva

  • Aibek Smagul

  • July 6, 2026

  • 0 min

Share

  • 1

    The study identified candidate miRNA markers for bronchopulmonary dysplasia (BPD) in very and extremely low birth weight infants.

  • 2

    A cohort of 41 preterm infants was analyzed, with 20 developing BPD and 21 not, using blood samples collected at 10–14 days of life.

  • 3

    Five miRNAs showed significantly higher levels in infants with BPD, with four selected based on statistical and performance criteria.

  • 4

    The integrated model combining clinical data and miRNA predictors achieved an adjusted AUC of 0.940, outperforming the clinical-only model.

  • 5

    Results indicate the potential of miRNA profiles for early BPD risk assessment, pending external validation and confirmation by RT-qPCR.

Original Source(s)

Integration of miRNA profiles and clinical data for early risk assessment of bronchopulmonary dysplasia in VLBW and ELBW newborn infants: a discovery study

  • by Iskander Isgandarov, Arailym Abilbayeva, Anel Tarabayeva, Dinara Yelyubayeva, Nishankul Bozhbanbayeva, Ingkar Okhas, Nuray Shaktay, Dana Yerbolat, Kristina Kovaleva, Zhanar Akhmetova, Zulfiya Kachiyeva, Aibek Smagul

  • July 6, 2026

Related Content

Fenestrated PECA exGraft Patch as a Novel Modifiable Internal Pulmonary Artery Band: A Case Report

Perinatal morphine exposure induces chromatin and transcriptomic remodeling to alter immune and metabolic function

Early initiation of therapy with vosoritide: case report. Description of the first Italian patient affected by achondroplasia treated with vosoritide before 2 years of age